- Home
- IMAB vs IMRX Comparison
IMAB vs IMRX Comparison
Compare IMAB & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- IMRX
- Stock Information
- Founded
- IMAB 2014
- IMRX 2008
- Country
- IMAB United States
- IMRX United States
- Employees
- IMAB N/A
- IMRX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- IMRX Health Care
- Exchange
- IMAB Nasdaq
- IMRX Nasdaq
- Market Cap
- IMAB 83.8M
- IMRX 73.2M
- IPO Year
- IMAB 2020
- IMRX 2021
- Fundamental
- Price
- IMAB $1.06
- IMRX $1.94
- Analyst Decision
- IMAB Strong Buy
- IMRX Buy
- Analyst Count
- IMAB 3
- IMRX 7
- Target Price
- IMAB $8.00
- IMRX $12.60
- AVG Volume (30 Days)
- IMAB 410.6K
- IMRX 369.8K
- Earning Date
- IMAB 08-28-2024
- IMRX 11-13-2024
- Dividend Yield
- IMAB N/A
- IMRX N/A
- EPS Growth
- IMAB N/A
- IMRX N/A
- EPS
- IMAB N/A
- IMRX N/A
- Revenue
- IMAB $3,492,091.00
- IMRX N/A
- Revenue This Year
- IMAB N/A
- IMRX N/A
- Revenue Next Year
- IMAB N/A
- IMRX N/A
- P/E Ratio
- IMAB N/A
- IMRX N/A
- Revenue Growth
- IMAB N/A
- IMRX N/A
- 52 Week Low
- IMAB $0.99
- IMRX $1.00
- 52 Week High
- IMAB $2.54
- IMRX $8.89
- Technical
- Relative Strength Index (RSI)
- IMAB 40.43
- IMRX 51.04
- Support Level
- IMAB $1.02
- IMRX $1.68
- Resistance Level
- IMAB $1.12
- IMRX $1.97
- Average True Range (ATR)
- IMAB 0.08
- IMRX 0.13
- MACD
- IMAB -0.01
- IMRX -0.01
- Stochastic Oscillator
- IMAB 20.00
- IMRX 71.72
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.